1. Home
  2. TV vs AGIO Comparison

TV vs AGIO Comparison

Compare TV & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Grupo Televisa S.A.

TV

Grupo Televisa S.A.

HOLD

Current Price

$2.61

Market Cap

1.5B

Sector

Industrials

ML Signal

HOLD

Logo Agios Pharmaceuticals Inc.

AGIO

Agios Pharmaceuticals Inc.

HOLD

Current Price

$27.19

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TV
AGIO
Founded
1969
2007
Country
Mexico
United States
Employees
26599
N/A
Industry
Broadcasting
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.7B
IPO Year
N/A
2013

Fundamental Metrics

Financial Performance
Metric
TV
AGIO
Price
$2.61
$27.19
Analyst Decision
Buy
Buy
Analyst Count
4
8
Target Price
$5.30
$38.88
AVG Volume (30 Days)
1.0M
717.6K
Earning Date
05-12-2026
04-29-2026
Dividend Yield
2.83%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$43,011,000.00
Revenue This Year
N/A
$76.75
Revenue Next Year
N/A
$170.73
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.96
$22.24
52 Week High
$3.49
$46.00

Technical Indicators

Market Signals
Indicator
TV
AGIO
Relative Strength Index (RSI) 31.74 44.32
Support Level $2.55 $26.75
Resistance Level $2.95 $29.37
Average True Range (ATR) 0.09 1.21
MACD -0.02 -0.06
Stochastic Oscillator 15.71 19.32

Price Performance

Historical Comparison
TV
AGIO

About TV Grupo Televisa S.A.

Televisa is one of the leading telecom firms in Mexico. Its cable arm, Izzi, holds networks that pass 20 million Mexican homes and provide broadband service to nearly 6 million customers. The firm is also one of the largest pay-television providers in Mexico, with nearly 4 million customers. Televisa owns Sky Mexico, the country's only satellite-TV provider, serving about 4 million customers. After merging its traditional media business into Univision, Grupo Televisa owns a 43% stake in the combined entity TelevisaUnivision. Grupo Televisa spun off several smaller businesses, including magazine publishing, three of Mexico's professional soccer teams, and Azteca Stadium in February 2024, under the name Ollamani.

About AGIO Agios Pharmaceuticals Inc.

Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.

Share on Social Networks: